Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 14, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,498	1,519	1,145	1,176	429	64
Market Cap Growth	37.37%	32.58%	-2.58%	173.76%	568.00%	321.43%
Enterprise Value	999	977	989	892	379	44
Last Close Price	18.85	19.17	21.78	29.21	19.77	16.45
PS Ratio	5047.00	5028.17	3647.53	663.46	144.94	61.23
PB Ratio	4.72	2.26	2.59	2.98	2.29	0.54
P/TBV Ratio	4.72	3.15	4.86	4.65	7.97	-
EV/Sales Ratio	3275.61	3236.51	3150.76	503.65	127.79	41.48
Debt / Equity Ratio	0.05	0.03	0.05	0.01	0.00	0.00
Asset Turnover	0.00	0	0.00	0.01	0.02	0.01
Quick Ratio	10.71	14.99	17.93	12.73	14.48	11.96
Current Ratio	11.01	15.43	18.27	12.93	14.68	12.14
Return on Equity (ROE)	-65.88%	-48.48%	-56.80%	-44.57%	-51.61%	-163.07%
Return on Assets (ROA)	-39.77%	-30.32%	-34.37%	-26.28%	-29.75%	-31.36%
Return on Capital (ROIC)	-42.60%	-32.26%	-36.80%	-28.52%	-32.28%	-35.04%
Earnings Yield	-17.91%	-17.78%	-20.76%	-11.05%	-18.49%	-172.21%
FCF Yield	-20.11%	-15.33%	-16.16%	-8.05%	-12.79%	-46.39%
Buyback Yield / Dilution	-41.68%	-51.68%	-39.48%	-169.22%	-235.07%	-70.27%

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q